Laura Morgan

According to Ms Skolnik, the appointment of Dr Gottlieb as the new FDA Commissioner may provide some semblance of stability to the FDA amidst potentially radical changes.

Read More ›

In the era of personalized medicine, identifying patients with cancer who will benefit most from a specific treatment is the Holy Grail. Currently, there is no test to identify effective chemotherapy before administering treatment. Read More ›

The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompt­­ed Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. Read More ›

In an effort to contain healthcare costs and to improve the quality of cancer care via shared decision-making, the ASCO Value in Cancer Care Task Force developed a conceptual framework to assess the value of new cancer drugs versus current standard-of-care treatments in 2 clinical settings: advanced disease and potentially curative disease. Read More ›

The April 14, 2015, repeal of the sustainable growth rate (SGR) formula for physician payments under Medicare is being welcomed by the healthcare community, including the American Society of Clinical Oncology (ASCO). Read More ›